Free Trial

Aktis Oncology (AKTS) 10K Form and Latest SEC Filings 2026

Aktis Oncology logo
$19.27 +0.27 (+1.42%)
As of 02:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Aktis Oncology SEC Filings & Recent Activity

Aktis Oncology (NASDAQ:AKTS) has submitted 38+ documents to the U.S. Securities and Exchange Commission (SEC) since 2024. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on April 16, 2026.

Form 4
Aktis Oncology, Inc. Reports Ownership Change on Apr. 16, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Aktis Oncology Files Current Report on Apr. 16, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Aktis Oncology SEC Filing History

Browse Aktis Oncology's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/16/2026 3:15 PM
Aktis Oncology (2035832) Issuer
Gormley Glenn (2127198) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2026 3:01 PM
Aktis Oncology (2035832) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/20/2026 4:44 PM
Aktis Oncology (2035832) Subject
MPM BIOVENTURES 2018, L.P. (1729505) Filed by
Form SCHEDULE 13D
01/20/2026 1:01 PM
Aktis Oncology (2035832) Subject
EcoR1 Capital, LLC (1587114) Filed by
Form SCHEDULE 13D
01/15/2026 5:01 AM
Aktis Oncology (2035832) Issuer
ELI LILLY & Co (59478) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/15/2026 5:02 AM
Aktis Oncology (2035832) Subject
ELI LILLY & Co (59478) Filed by
Form SCHEDULE 13D
01/14/2026 5:17 PM
Aktis Oncology (2035832) Issuer
GADICKE ANSBERT (1134655) Reporting
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Oncology Impact Private Investment Fund 2, L.P. (2104306) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 5:19 PM
Aktis Oncology (2035832) Issuer
EVNIN LUKE (1134657) Reporting
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (1734817) Reporting
MPM BIOVENTURES 2018 (0) B
MPM BioVentures 2018 GP LLC (1818701) Reporting
MPM BioVentures 2018 LLC (1818702) Reporting
MPM BIOVENTURES 2018, L.P. (1729505) Reporting
MPM Oncology Innovations Fund GP LLC (1857903) Reporting
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 5:20 PM
Aktis Oncology (2035832) Issuer
Foley Todd (1473930) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 3:58 PM
Aktis Oncology (2035832) Subject
VV Manager II, LLC (1824569) Filed by
Form SCHEDULE 13D
01/12/2026 7:28 PM
Aktis Oncology (2035832) Issuer
EcoR1 Capital, LLC (1587114) Reporting
NODELMAN OLEG (1454385) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:10 PM
Aktis Oncology (2035832) Issuer
Vida Ventures II, LLC (1776851) Reporting
VIDA VENTURES II-A, LLC (1781930) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 3:49 PM
Aktis Oncology (2035832) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/12/2026 4:00 PM
Aktis Oncology (2035832) Issuer
Segal Lloyd Mitchell (1477123) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:00 PM
Aktis Oncology (2035832) Issuer
Kim Helen Susan (1422772) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 3:03 PM
Aktis Oncology (2035832) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2026 4:01 PM
Aktis Oncology (2035832) Filer
Form 424B4
01/08/2026 11:15 PM
Aktis Oncology (2035832) Filer
Form EFFECT
01/08/2026 8:19 PM
Aktis Oncology (2035832) Issuer
Kuvalanka Kyle D. (1638904) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:00 PM
Aktis Oncology (2035832) Issuer
Sherman Michael A. (1509463) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:02 PM
Aktis Oncology (2035832) Issuer
Czibere Akos (2049427) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:02 PM
Aktis Oncology (2035832) Issuer
Feldman Paul L (2050705) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:03 PM
Aktis Oncology (2035832) Issuer
Foley Todd (1473930) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:03 PM
Aktis Oncology (2035832) Issuer
Ron-Bigger Shulamit (2049407) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:04 PM
Aktis Oncology (2035832) Issuer
EVNIN LUKE (1134657) Reporting
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (1734817) Reporting
MPM BIOVENTURES 2018 (0) B
MPM BioVentures 2018 GP LLC (1818701) Reporting
MPM BioVentures 2018 LLC (1818702) Reporting
MPM BIOVENTURES 2018, L.P. (1729505) Reporting
MPM Oncology Innovations Fund GP LLC (1857903) Reporting
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:05 PM
Aktis Oncology (2035832) Issuer
RODEN MATTHEW (1828130) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:05 PM
Aktis Oncology (2035832) Issuer
Segal Lloyd Mitchell (1477123) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:05 PM
Aktis Oncology (2035832) Issuer
GADICKE ANSBERT (1134655) Reporting
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Oncology Impact Private Investment Fund 2, L.P. (2104306) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:08 PM
Aktis Oncology (2035832) Issuer
Herrmann Ken (2049757) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 8:09 PM
Aktis Oncology (2035832) Issuer
Kim Helen Susan (1422772) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 7:49 PM
Aktis Oncology (2035832) Issuer
EcoR1 Capital, LLC (1587114) Reporting
NODELMAN OLEG (1454385) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 7:57 PM
Aktis Oncology (2035832) Issuer
Thistle Mary (1317917) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 7:41 PM
Aktis Oncology (2035832) Issuer
Vida Ventures II, LLC (1776851) Reporting
VIDA VENTURES II-A, LLC (1781930) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2026 11:44 AM
Aktis Oncology (2035832) Filer
Form CERT
01/07/2026 6:19 AM
Aktis Oncology (2035832) Filer
Form S-1/A
01/05/2026 5:31 AM
Aktis Oncology (2035832) Filer
Form S-1/A
12/19/2025 3:02 PM
Aktis Oncology (2035832) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Aktis Oncology SEC Filings - Frequently Asked Questions

Aktis Oncology (AKTS) has submitted 38+ filings to the SEC since 2024. You can browse the complete history or filter by form type using the tools above.

Aktis Oncology's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 4 submitted on April 16, 2026. This was an insider ownership change filed by 4 - Aktis Oncology, Inc. (0002035832) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:AKTS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners